STOCK TITAN

Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Silber Jeffrey reported acquisition or exercise transactions in this Form 4 filing.

Ironwood Pharmaceuticals Inc granted its SVP, CMO and Head of Research & Drug Development, Jeffrey Silber, a new-hire restricted stock unit award covering 137,036 shares of Class A Common Stock. The award vests 25% of the shares on each approximate anniversary of the grant, resulting in direct ownership of 137,036 shares.

Positive

  • None.

Negative

  • None.
Insider Silber Jeffrey
Role SVP, CMO, Head-Res&Drug
Type Security Shares Price Value
Grant/Award Class A Common Stock F1 137,036 $0.00 $0.00
Holdings After Transaction: Class A Common Stock — 137,036 shares (Direct)
Footnotes (1)
  1. F1. The restricted stock unit award, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
Restricted stock units granted 137,036 shares New-hire equity award of Class A Common Stock
Grant price US$0.00 per share Equity award granted without cash payment
Shares held after grant 137,036 shares Direct Class A Common Stock ownership following award
Annual vesting portion 25% Portion of RSU award vesting on each approximate anniversary
restricted stock unit financial
"The restricted stock unit award, granted as a new hire award, vests as to 25%"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
new hire award financial
"The restricted stock unit award, granted as a new hire award, vests as to 25%"
Class A Common Stock financial
"shares of Class A Common Stock on each approximate anniversary of the grant"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity award did Jeffrey Silber receive from IRWD?

Jeffrey Silber received a restricted stock unit award covering 137,036 shares of Ironwood Pharmaceuticals’ Class A Common Stock as a new-hire grant. This equity compensation was reported as directly owned following the award, with no cash purchase price per share disclosed.

How do the restricted stock units granted by IRWD to Jeffrey Silber vest?

The restricted stock unit award vests in four equal installments, with 25% of the shares vesting on each approximate anniversary of the grant. This schedule spreads vesting over several years, aligning the award with Silber’s continued service at Ironwood Pharmaceuticals.

How many IRWD shares does Jeffrey Silber hold after this grant?

After the reported grant, Jeffrey Silber holds 137,036 shares of Ironwood Pharmaceuticals’ Class A Common Stock in direct ownership. This figure matches the size of the new-hire restricted stock unit award disclosed in the insider transaction report.

Was Jeffrey Silber’s IRWD equity grant made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked, indicating the reported equity award was not granted pursuant to a Rule 10b5-1 trading plan. It is disclosed simply as a new-hire restricted stock unit grant.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Silber Jeffrey

(Last)(First)(Middle)
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, CMO, Head-Res&Drug
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock07/20/2026A(1)137,036A$0137,036D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The restricted stock unit award, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
/s/ Amir Vitale, Attorney-in-Fact07/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)